eFFECTOR Therapeutics, Inc. EFTR
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $200.0K
- P/E
- 0.0×
Follow EFTR
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
| 1,737.63% | 3,771.56% | (946.56%) | (335.14%) |
+8 more TTM periods Free account |
|
| (141.18%) | (144.34%) | (126.53%) | (105.73%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(3,976.00%) | 615.52% | 884.81% | (1,529.48%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(7.15) | (13.56) | (12.47) | (16.36) | |
Free Cash Flow |
(29.19) | (29.65) | (30.82) | (31.29) | |
Capital Expenditures |
— | (0.10) | (0.06) | (0.10) | |
Piotroski F-Score |
— | — | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(64.69%) | (92.46%) | (92.89%) | (66.60%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.09 | 0.08 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 3,839.26 | 5,296.15 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.83 | 0.86 | 0.84 | |
Depreciation/Fixed assets |
(1.59) | (2.59) | (1.64) | (1.19) | |
Capex/Depreciation |
0.00 | 0.27 | 0.14 | 0.39 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.15) | (13.51) | (12.45) | (16.30) | |
Capex per Share |
0.00 | (0.04) | (0.02) | (0.05) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates